Search

917 Result(s)
Sort by

Living with heart failure

Living with heart failure

Hear Patricia’s story on the impact that heart failure can have on mental health and the importance of finding support networks.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
The Angels Initiative

The Angels Initiative

The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
Combating complex diseases with data

Combating complex diseases with data

How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
NEJM-IL-36-Phase-1-GPP-data

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
EHS management approach

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Global mobility

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease